The costs of research and development (R&D) for drugs has been a recurrent point of discussion in the continuing debate about high prices of drugs. Most recently, the Trump administration’s
Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs argues that foreign countries “Are not paying an appropriate share of the necessary research and development to bring innovative drugs to the market,”
1 implying a direct association between the costs of R&D and drug prices.